Clinical Takeaway
In a study of individuals at clinical high risk for psychosis, a single dose of CBD was shown to modulate the relationship between hippocampal glutamate levels and prefrontal brain activation during verbal memory tasks. This suggests CBD may act on glutamate-related brain circuitry that is disrupted in the early stages of psychosis. These findings support a neurochemical basis for CBD’s potential role in addressing memory and cognitive deficits associated with psychosis risk.
Citation: Shi Yiling et al.. A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.. Psychiatry research. Neuroimaging. 2026. PMID: 41337954.
Design: 5 Journal: 0 N: 1 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Small sample — underpowered for subgroup analysis
Abstract: BACKGROUND: Cannabidiol (CBD) is being studied as a potential intervention for the people at clinical high risk for psychosis (CHR), though the mechanisms underlying its effects are not fully understood. Previous studies indicate that a single dose of CBD can normalize alterations in memory-related brain activation and modulate hippocampal glutamate levels in the early stages of psychosis. This study aimed to examine the acute effects of CBD on the relationship between hippocampal glutamate levels and brain activation during verbal memory in individuals at CHR. METHODS: A total of thirty-three participants (n = 33) at CHR were randomly assigned to receive a single 600 mg dose of CBD (CHR-CBD) or a placebo capsule (CHR-PLB). Age-matched healthy controls (HC) (n = 19) received no study drugs. Participants underwent MRI scanning while performing a verbal learning task, and proton magnetic resonance spectroscopy to measure hippocampal glutamate levels. Effect of group x hippocampal glutamate interactions on brain activation was tested. RESULTS: CHR-PLB showed positive correlation between hippocampal glutamate levels and dorsolateral prefrontal cortex (dlPFC) (Pcorr. = 0.0039) activation compared to HC during both verbal encoding and recall. Under a single dose of CBD, the glutamate-dlPFC activation relationship was negative and significantly different compared to placebo in CHR individuals (Pcorr. = 0.0001) during both verbal encoding and recall. The reversed correlation in CBD group was also observed in the parahippocampal gyrus (Pcorr. = 0.0022) and amygdala (Pcorr. = 0.0019) during verbal recall. CONCLUSIONS: These findings suggest that CBD may normalise disrupted hippocampal-prefrontal glutamatergic coupling in CHR, highlighting its potential to target the neurochemical mechanisms underlying cognitive impairment.
What This Study Teaches Us
A single 600 mg dose of CBD reverses an abnormal brain pattern seen in people at clinical high risk for psychosis, where high hippocampal glutamate was coupled with excessive prefrontal activation during memory tasks. After CBD, this relationship flipped to resemble the healthier pattern seen in controls, suggesting CBD may restore disrupted glutamate signaling between memory and executive brain regions.
Why This Matters Clinically
People at clinical high risk for psychosis face real risk of progression, and current preventive options are limited. If CBD can acutely normalize this specific neurochemical-functional coupling without the side effects of antipsychotics, it could become a valuable early intervention. However, a single dose effect does not yet tell us whether repeated dosing maintains benefit or whether this brain change translates to clinical protection.
Study Snapshot
| Study Design | Randomized controlled trial with parallel groups (CBD vs. placebo in CHR; healthy controls observation arm) |
| Population | 33 individuals at clinical high risk for psychosis (mean age not specified), plus 19 age-matched healthy controls |
| Intervention | Single 600 mg oral dose of CBD or placebo capsule; no mention of timing relative to scanning or repeated dosing |
| Primary Outcome | Correlation between hippocampal glutamate levels (measured by MR spectroscopy) and dorsolateral prefrontal cortex activation (measured by fMRI during verbal memory task) |
| Key Result | CBD reversed the abnormal positive glutamate-dlPFC correlation seen in placebo-treated CHR participants to a negative correlation (p=0.0001), matching the healthier pattern in controls during both encoding and recall |
Where This Paper Deserves Skepticism
The sample size is modest (33 CHR, 19 controls) and the abstract does not specify baseline demographics, clinical severity, or symptom measures, limiting generalizability. The study measures only acute effects of a single dose, so we have no data on whether repeated dosing is effective, whether effects persist, or whether this neuroimaging change predicts clinical outcomes like symptom reduction or psychosis prevention. The abstract does not report whether participants or raters were blind to condition, which is concerning for bias. Finally, the relationship between this specific neurochemical-functional coupling and actual clinical risk remains unclear, so normalizing it in brain imaging does not yet prove clinical benefit.
Dr. Caplan’s Take
This is an interesting mechanistic study that shows CBD can acutely shift a disrupted brain pattern in a direction that looks healthier. The specificity of the finding, the use of spectroscopy to measure glutamate, and the consistency across multiple brain regions is encouraging. That said, I would not overread this as evidence for clinical prevention yet. We need longitudinal data showing that repeated CBD dosing maintains this effect, that it correlates with symptom improvement or risk reduction, and that it outperforms existing early interventions. For now, this belongs in the preclinical-to-clinical pipeline, not in clinical practice.
Clinical Bottom Line
CBD shows promise in reversing a specific neurochemical abnormality in people at high risk for psychosis, but a single-dose neuroimaging study cannot yet support clinical use. Next steps should include longer-term dosing trials with clinical endpoints and head-to-head comparisons to standard early interventions.
|
Have thoughts on this? Share it:
